Clavix 75mg Tablet

Clavix 75mg tablet is a type of antiplatelet agent that prevents blood from clumping together, which reduces the formation of blood clots. These drugs are commonly used to prevent heart attacks, strokes, and other cardiovascular events in patients.

Its active ingredient is Clopidogrel (75mg). It works by blocking the ADP receptor on platelets, which prevents their aggregation and helps maintain smooth blood flow in the arteries. Do not stop suddenly without consulting the doctor, as it may increase the risk of a heart attack or stroke.

• Reduces the risk of heart attack or stroke,
• Commonly used for heart protection

Some patients may experience mild and some may experience severe symptoms while using Clavix 75mg tablet, like any other medication. Common side effects include:

• Diarrhea
• Allergic reaction on the skin
• Bruise
• Hematoma
• Nosebleeds
• Gastrointestinal bleeding
• Abdominal pain
• Dyspepsia
• Indigestion
• Chest pain

• Clavix 75mg tablet should be taken orally with a glass of water; do not crush, chew, or break the tablet. The medicine can be taken with or without food at the same time every day to enhance the effectiveness of the medication.
• Doctors typically prescribed 75mg at once on a daily basis. A healthcare professional may adjust the dose based on the patient's response to the treatment.
  
  

Clopidogrel works by preventing platelets in the blood from sticking together, reducing the formation of blood clots in the body. This helps keep blood flowing through arteries and prevents blockages. The medicine reduces the risk of heart attacks, stroke, and blood vessel blockages in people with heart disease or after certain heart procedures. It specifically blocks the ADP receptor on platelets, inhibiting platelet activation and aggregation.

• Coukell, A. J., & Markham, A. (1997). Clopidogrel. Drugs, 54(5), 745-50 https://pubmed.ncbi.nlm.nih.gov/9360060/
• Quinn, M. J., & Fitzgerald, D. J. (1999). Ticlopidine and clopidogrel. Circulation, 100(15), 1667-1672. https://pubmed.ncbi.nlm.nih.gov/10517740/
• Sangkuhl, K., Klein, T. E., & Altman, R. B. (2010). Clopidogrel pathway. Pharmacogenetics and genomics, 20(7), 463-465. https://pubmed.ncbi.nlm.nih.gov/20440227/
• Nguyen, T. A., Diodati, J. G., & Pharand, C. (2005). Resistance to clopidogrel: a review of the evidence. Journal of the American College of Cardiology, 45(8), 1157-1164. https://pubmed.ncbi.nlm.nih.gov/15837243/
• Caplain, H., Donat, F., Gaud, C., & Necciari, J. (1999, January). Pharmacokinetics of clopidogrel. In Seminars in thrombosis and hemostasis (Vol. 25, pp. 25-28). https://pubmed.ncbi.nlm.nih.gov/10440419/